NYSEAMERICAN:LCTX Lineage Cell Therapeutics (LCTX) Stock Forecast, Price & News $1.11 -0.02 (-1.77%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$1.10▼$1.1550-Day Range N/A52-Week Range$1.02▼$1.58Volume767,157 shsAverage Volume507,057 shsMarket Capitalization$194.24 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesOptions ChainShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesOptions ChainShort InterestSocial Media Lineage Cell Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside440.5% Upside$6.00 Price TargetShort InterestBearish3.55% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.15) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Lineage Cell Therapeutics has a forecasted upside of 440.5% from its current price of $1.11.Amount of Analyst CoverageLineage Cell Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted3.55% of the outstanding shares of Lineage Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverLineage Cell Therapeutics has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Lineage Cell Therapeutics has recently increased by 0.65%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLineage Cell Therapeutics does not currently pay a dividend.Dividend GrowthLineage Cell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LCTX. Previous Next 0.6 News and Social Media Coverage Search Interest8 people have searched for LCTX on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.10% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.42% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Lineage Cell Therapeutics are expected to decrease in the coming year, from ($0.15) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lineage Cell Therapeutics is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lineage Cell Therapeutics is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLineage Cell Therapeutics has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) StockLineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.Read More LCTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LCTX Stock News HeadlinesSeptember 19, 2023 | finance.yahoo.comLineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023September 13, 2023 | finance.yahoo.comRG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA CongressOctober 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 11, 2023 | finance.yahoo.comLineage to Present at 2023 International Spinal Research Trust Network MeetingSeptember 6, 2023 | finance.yahoo.comLineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna TherapeuticsSeptember 6, 2023 | benzinga.comEXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna TherapeuticsSeptember 1, 2023 | markets.businessinsider.comRobert W. Baird Sticks to Its Buy Rating for Lineage Therap (LCTX)August 29, 2023 | finance.yahoo.comLineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment ConferenceOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.August 15, 2023 | markets.businessinsider.comMaxim Group Remains a Buy on Lineage Therap (LCTX)August 13, 2023 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | finance.yahoo.comQ2 2023 Lineage Cell Therapeutics Inc Earnings CallAugust 11, 2023 | investing.comLineage Cell Therapeutics (LCTX) Earnings Dates & ReportsAugust 10, 2023 | finance.yahoo.comLineage Cell (LCTX) Reports Q2 Loss, Tops Revenue EstimatesAugust 10, 2023 | finance.yahoo.comLineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 9, 2023 | benzinga.comLineage Cell Therapeutics Earnings PreviewAugust 8, 2023 | finance.yahoo.comU.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue EstimatesAugust 3, 2023 | thestreet.comLineage Cell Therapeutics, Inc.August 3, 2023 | finance.yahoo.comLineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023July 26, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for Lineage Therap (LCTX)July 24, 2023 | msn.comLineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune ResponseJuly 24, 2023 | finance.yahoo.comLineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung CancerJuly 19, 2023 | finance.yahoo.comLCTX - Lineage Cell Therapeutics, Inc.July 12, 2023 | fool.comLineage Cell Therapeutics (NYSEMKT: LCTX)July 7, 2023 | markets.businessinsider.comB.Riley Financial Keeps Their Buy Rating on Lineage Therap (LCTX)May 22, 2023 | finance.yahoo.comLineage Cell Therapeutics Expected to Be Added to Russell 3000® IndexMay 16, 2023 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call TranscriptSee More Headlines Receive LCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LCTX Company Calendar Last Earnings8/10/2023Today10/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:LCTX CUSIPN/A CIKN/A Webwww.lineagecell.com Phone(442) 287-8963Fax510-521-3389Employees70Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+440.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,270,000.00 Net Margins-209.27% Pretax Margin-221.85% Return on Equity-30.40% Return on Assets-18.36% Debt Debt-to-Equity RatioN/A Current Ratio3.02 Quick Ratio3.02 Sales & Book Value Annual Sales$14.70 million Price / Sales13.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book2.64Miscellaneous Outstanding Shares174,990,000Free Float125,816,000Market Cap$194.24 million OptionableOptionable Beta1.67 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Brian M. Culley M.A. (Age 52)M.B.A., CEO, Pres & Director Comp: $944.15kMs. Jill Ann Howe (Age 47)CFO & Principal Financial and Accounting Officer Comp: $125.52kMr. George A. Samuel III (Age 42)J.D., Gen. Counsel & Company Sec. Comp: $560.95kIoana C. HoneDirector of Investor RelationsDr. Gary S. Hogge D.V.M. (Age 54)Dvm, Ms, Ph.D., Sr. VP of Clinical & Medical Affairs Ms. Brandi L. Roberts CPA (Age 49)M.B.A., Consultant Mr. William Annett MBA (Age 69)Pres & CEO of OncoCyte Corp. Ms. Alexandra HernandezSr. Director of Fin. & ControllerDr. Harold D. Waitz (Age 81)VP of Regulatory Affairs & Quality Control More ExecutivesKey CompetitorsMesoblastNASDAQ:MESOInnate PharmaNASDAQ:IPHAScilexNASDAQ:SCLXFennec PharmaceuticalsNASDAQ:FENCOrchard TherapeuticsNASDAQ:ORTXView All CompetitorsInstitutional OwnershipBarclays PLCBought 12,075 shares on 9/21/2023Ownership: 0.015%California State Teachers Retirement SystemBought 42,928 shares on 8/21/2023Ownership: 0.025%Nuveen Asset Management LLCBought 515,445 shares on 8/16/2023Ownership: 0.295%Raffles Associates LPBought 60,793 shares on 8/15/2023Ownership: 0.913%Wells Fargo & Company MNBought 52,963 shares on 8/15/2023Ownership: 0.046%View All Institutional Transactions LCTX Stock - Frequently Asked Questions Should I buy or sell Lineage Cell Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LCTX shares. View LCTX analyst ratings or view top-rated stocks. What is Lineage Cell Therapeutics' stock price forecast for 2023? 3 brokerages have issued 1-year target prices for Lineage Cell Therapeutics' stock. Their LCTX share price forecasts range from $5.00 to $7.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 440.5% from the stock's current price. View analysts price targets for LCTX or view top-rated stocks among Wall Street analysts. How have LCTX shares performed in 2023? Lineage Cell Therapeutics' stock was trading at $1.46 at the beginning of 2023. Since then, LCTX shares have decreased by 24.0% and is now trading at $1.11. View the best growth stocks for 2023 here. How were Lineage Cell Therapeutics' earnings last quarter? Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The company had revenue of $3.23 million for the quarter, compared to analyst estimates of $2.65 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 30.40% and a negative net margin of 209.27%. What other stocks do shareholders of Lineage Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN). What is Lineage Cell Therapeutics' stock symbol? Lineage Cell Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LCTX." How do I buy shares of Lineage Cell Therapeutics? Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lineage Cell Therapeutics' stock price today? One share of LCTX stock can currently be purchased for approximately $1.11. How much money does Lineage Cell Therapeutics make? Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a market capitalization of $194.24 million and generates $14.70 million in revenue each year. The company earns $-26,270,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis. How can I contact Lineage Cell Therapeutics? Lineage Cell Therapeutics' mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The official website for the company is www.lineagecell.com. The company can be reached via phone at (442) 287-8963, via email at ir@lineagecell.com, or via fax at 510-521-3389. This page (NYSEAMERICAN:LCTX) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.